Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128077 | 0.89 | TNKS (0.32) | SIRT2SIRT1TP53MAPTALOX15 | |
| SCHEMBL10128074 | 0.82 | MAPT (0.34) | SIRT2SIRT1HCRTR1TP53MAPT | |
| SCHEMBL10127563 | 0.81 | POLB (0.37) | TP53MAPT | |
| SCHEMBL10128081 | 0.81 | IKBKE (0.31) | MAPTRAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10128065 | 0.81 | MAPT (0.38) | SIRT2SIRT1TP53MAPTALOX15 | |
| SCHEMBL10127925 | 0.81 | ATM (0.30) | HCRTR1TP53MAPTALOX15MAPK1 | |
| SCHEMBL10148819 | 0.80 | MAPT (0.34) | SIRT2SIRT1HCRTR1TP53MAPT | |
| SCHEMBL10128073 | 0.80 | RAB9A (0.33) | SIRT2SIRT1HCRTR1TP53MAPT | |
| SCHEMBL889841 | 0.80 | SMN1; SMN2 (0.41) | NPSR1TP53MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL10128115 | 0.80 | MAPT (0.39) | SIRT2SIRT1TP53MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034486-B2 | Triazole derivative, heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) | 2015-05-19 | — | — | US | disclosed |
| US-9034486-B2 | Triazole derivative, heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) | 2015-05-19 | — | — | US | disclosed |
| WO-2012017842-A1 | TRIAZOLE DERIVATIVE, HETEROCYCLIC COMPOUND, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-02-09 | — | — | WO | disclosed |
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | HTR3D, KCNQ4, KCNQ3 | NPSR1 2321/4885SIRT2 2521/4885SIRT1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.